


Pafuramidine

Chemical Properties

| | |
|-------------------|--|
| CAS No. : | 186953-56-0 |
| Formula: | C ₂₀ H ₂₀ N ₄ O ₃ |
| Molecular Weight: | 364.4 |
| Storage: | Store at low temperature, Store under nitrogen Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i> |



Biological Description

| | |
|---------------|---|
| Description | Pafuramidine (DB289) is an experimental prodrug of the orally active metabolite DB75, a potent antiparasitic compound with anti-malarial activity used in the study of parasitic infections and sleeping sickness. |
| Targets(IC50) | Antibiotic, Parasite |
| In vitro | The results of this investigation suggest that DB75 inhibits mitochondrial function. Yeast cells relying upon mitochondrial metabolism for energy production are especially sensitive to DB75 [1]. |
| In vivo | In monkeys infected with <i>Trypanosoma cruzi</i> , treatment with oral Pafuramidine at doses of 1, 3 and 10 mg/kg for five consecutive days on the seventh day post-infection (p.i.) of early infection showed that Pafuramidine treatment benefited most of the monkeys, and at the end of the experiment all monkeys except group 1 had improved body weights and PCVs, and in some individuals parasitemia and cerebrospinal fluid parasitemia had cleared. [1] |

Solubility Information

| | |
|---------------------|---|
| Solubility | DMSO: 33.33 mg/mL (91.47 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.49 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.7442 mL | 13.7212 mL | 27.4424 mL |
| 5 mM | 0.5488 mL | 2.7442 mL | 5.4885 mL |
| 10 mM | 0.2744 mL | 1.3721 mL | 2.7442 mL |
| 50 mM | 0.0549 mL | 0.2744 mL | 0.5488 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Mdachi RE, et al. Efficacy of the novel diamidine compound 2,5-Bis(4-amidinophenyl)-furan-bis-O-Methylamidoxime (Pafuramidine, DB289) against *Trypanosoma brucei rhodesiense* infection in vervet monkeys after oral administration. *Antimicrob Agents Chemother.* 2009 Mar;53(3):953-7.
- Pohlig G, et al. Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial. *PLoS Negl Trop Dis.* 2016 Feb 16;10(2):e0004363.
- Chen D, et al. Pafuramidine for *Pneumocystis jiroveci* pneumonia in HIV-infected individuals. *Expert Rev Anti Infect Ther.* 2007 Dec;5(6):921-8.
- Purfield AE, et al. Interactions of DB75, a novel antimalarial agent, with other antimalarial drugs in vitro. *Antimicrob Agents Chemother.* 2008 Jun;52(6):2253-5.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481